Gasmi Abdelkader, Guenifi Wahiba, Ouyahia Amel, Rais Mounira, Boukhrissa Houda, Hachani Abderahmen, Mechakra Salah, Laouamri Slimen, Touabti Abderezak, Lacheheb Abdelmadjid
Division of Infectious Diseases Teaching Hospital, Faculty of Medicine, University Ferhat Abbes Setif, Setif, Algeria.
Division of Epidemiology Teaching Hospital, Faculty of Medicine, University Ferhat Abbes Setif, Setif, Algeria.
S Afr J Infect Dis. 2019 Oct 23;34(1):110. doi: 10.4102/sajid.v34i1.110. eCollection 2019.
No recent data are available on hepatitis delta virus (HDV) prevalence in Algeria. For this reason we conducted an epidemiological study, cross-sectional seroprevalence of HDV in the region of Setif.
Between 2011 and 2014, sera samples of 500 patients (carrying HBsAg) admitted to the Division of Infectious Diseases Teaching Hospital, Setif (east of Algeria), were tested for anti-HDV-IgG ab (ETI-AB-DeltaK-2).
The prevalence of HDV obtained is estimated at 2.4%. The prevalence ranges from 1% in chronic hepatitis to 11.1% in cirrhotic hepatitis (low endemic area). Seropositivity rate is closely correlated with age (Odds ratio [OR] = 9.98, = 0.000) and gender (OR = 0.24, = 0.025); it reaches 58.3% in the age group of 51-60 years and 0% in children (age group 1-15 years); it represents 75% in females and 25% in males. The presence of familial cases of HBsAg positive (OR = 4.54, = 0.006), the endoscopic procedure (OR = 6.54, = 0.000) and tattooing (OR = 20, = 0.000) were found to be the transmission risk factors. A statistically significant relationship was found between the positivity of anti-HDV and advanced liver disease, cirrhosis (OR = 9. 16, = 0.000). A significant correlation was found between the positivity of anti-HDV with diabetes (OR = 6.83, = 0.000), obesity (OR = 4.19, = 0.009) and viral suppression B (OR = 5.69, = 0.003).
Our results show that HDV infection is low in Algeria. Research for total anti-HDV should be part of the initial assessment of patient care with viral hepatitis B as well as the prevalence of other viruses (hepatitis C [HCV] and HIV). A multicentre study should be carried out to know the importance of HDV infection and identify the risk groups.
目前尚无关于阿尔及利亚丁型肝炎病毒（HDV）流行率的最新数据。因此，我们在塞提夫地区开展了一项关于HDV横断面血清流行率的流行病学研究。
2011年至2014年期间，对阿尔及利亚东部塞提夫传染病教学医院收治的500例携带乙肝表面抗原（HBsAg）患者的血清样本进行丁型肝炎病毒IgG抗体检测（ETI-AB-DeltaK-2）。
HDV流行率估计为2.4%。流行率范围从慢性肝炎中的1%到肝硬化肝炎中的11.1%（低流行地区）。血清阳性率与年龄（优势比[OR]=9.98，P=0.000）和性别（OR=0.24，P=0.025）密切相关；在51-60岁年龄组中达到58.3%，在儿童（1-15岁年龄组）中为0%；女性占75%，男性占25%。乙肝表面抗原阳性家族病例的存在（OR=4.54，P=0.006）、内镜检查（OR=6.54，P=0.000）和纹身（OR=20，P=0.000）被发现是传播风险因素。在抗HDV阳性与晚期肝病、肝硬化之间发现了统计学上的显著关系（OR=9.16，P=0.000）。在抗HDV阳性与糖尿病（OR=6.83，P=0.000）、肥胖（OR=4.19，P=0.009）和病毒抑制B（OR=5.69，P=0.003）之间发现了显著相关性。
我们的结果表明阿尔及利亚的HDV感染率较低。对总抗HDV的检测应成为乙肝病毒感染患者初始评估以及其他病毒（丙型肝炎病毒[HCV]和人类免疫缺陷病毒[HIV]）流行率评估的一部分。应开展多中心研究以了解HDV感染的重要性并确定风险人群。
